British American Tobacco p.l.c. (BTAFF)

British American Tobacco manufactures and sells cigarettes, cigars, pipe tobacco, and oral nicotine products across more than 180 countries. It is one of the oldest and largest tobacco companies in the world, tracing its roots to 1902, and it remains a fixture of the London stock exchange and the portfolios of dividend-focused investors. The company generates cash reliably, returns enormous sums to shareholders, and sells a product that, despite decades of regulation and public-health campaigns, continues to command price-inelastic demand in many markets around the world.

The fortress and the siege

British American Tobacco has, for more than a century, built one of the simplest and most reliable cash machines in global commerce: grow tobacco in low-cost regions, manufacture cigarettes, tax them heavily in wealthy countries, and collect the proceeds. The profit margins on cigarettes are extraordinary — often 40 to 50 percent or higher — because the cost of goods is low and consumers have few substitutes once a brand captures their loyalty.

The problem, which will define the company for the foreseeable future, is that the volume of cigarettes sold in the developed world has been shrinking for decades. Smoking rates in North America and Western Europe have fallen from double digits to single digits as public campaigns, tax hikes, and regulation have reduced demand. BAT’s response has followed a predictable arc: raise prices to offset falling volume, invest in so-called “new nicotine” products — heated tobacco, vaping, oral nicotine pouches — and acquire rivals to consolidate market share in the segments that remain.

The paradox: BAT is a far more profitable company today than it was in 1990, and the stock is cheaper than ever.

This paradox lies at the heart of understanding BAT through boom and bust. In upswings, when discretionary spending is high and young adults in emerging markets take up smoking, BAT’s volumes tick upward and the stock typically does well. In downturns, when consumers cut back on discretionary purchases and smoking rates fall fastest among lower-income groups, BAT’s volumes sag — but the company’s pricing power often keeps earnings stable or rising anyway, because it has the scale and brand equity to raise prices without losing too many customers. The real damage to BAT’s investment case comes not from recessions, but from the long, secular decline in smoking itself, which no business cycle can reverse.

How BAT makes money

Cigarettes are the overwhelming majority of BAT’s revenue and the largest driver of profit. The company sells dozens of brands across most markets: Dunhill, Pall Mall, Lucky Strike, and Kent are among the most recognizable globally, alongside hundreds of regional and premium variants. The price per pack varies enormously by country — a pack costs pennies in some emerging markets and ten or fifteen times that in high-tax jurisdictions like Australia and Scandinavia. That price variation is a feature, not a bug. In wealthy, mature markets where smoking is culturally declining, BAT relies on price to maintain margins as volumes fall; in growth markets where a young population is taking up smoking for the first time, lower prices compete on volume.

The new-nicotine segment — vaping, heated tobacco, and oral pouches — remains a far smaller share of profit than combustible cigarettes but is growing. The company has invested heavily here both through organic product development and through acquisition. The economics of this segment are different: margins are lower, competition is fiercer and less regulated, and brand loyalty has not yet calcified. But the logic is clear: as cigarette volumes fall, these products offer BAT a way to stay in the nicotine business without ceding customers to competitors.

Beyond the core nicotine business, BAT has a modest cannabis operation in Canada and elsewhere, though this contributes little to overall results and carries significant regulatory uncertainty.

The company’s approach to returns on capital is to harvest cash. BAT generates free cash flow far in excess of its capital needs and has historically returned the vast majority of it to shareholders through dividends and buybacks. The dividend yield is usually high by global standards, and dividend growth has been consistent even through periods of volume decline — a fact that has made BAT particularly attractive to retirees and income-focused investors, though it also raises sustainability questions as the core business shrinks.

The cyclical squeeze

BAT’s behavior across economic cycles is counterintuitive. In boom times, when incomes rise and discretionary spending expands, you might expect cigarette demand to grow. It sometimes does, but not reliably. What matters more is what happens at the margin: do new smokers or younger smokers enter the market, or do existing smokers smoke more? That tends to happen in emerging markets during growth phases. In developed markets, boom times often bring no volume benefit because smoking is already at a structural low and consumer preferences have shifted.

In downturns, traditional demand theory suggests cigarettes should prove resilient — they are an inelastic good, after all. That is partly true. Lower-income smokers will not quit when their paycheques shrink; they will instead cut spending elsewhere. But there is a floor: in severe recessions, when employment falls sharply and poverty deepens, even cigarette demand can sag, because some portion of consumers cut out the habit entirely or simply cannot afford it. The 2008 financial crisis and the 2020 pandemic saw temporary volume dips in BAT’s results, though pricing adjustments and cost discipline kept profits more stable than volumes suggested they would be.

The real cyclical pressure on BAT today is the reverse: during periods of prosperity and optimism, health consciousness tends to rise, regulation tightens, and young adults are less likely to take up smoking. So the company’s growth is most likely to come during periods of economic hardship or low education and public-health investment in emerging markets — the opposite of the pattern that favours most consumer stocks.

The durable franchise and the secular headwind

What keeps BAT valuable, despite the shrinking addressable market, is the power of its established brands and the loyalty of its remaining customer base. A person who smokes a particular cigarette brand for decades will not easily switch, even if prices rise. That customer base is disproportionately concentrated in emerging markets — the Philippines, Indonesia, Eastern Europe, parts of Africa — where BAT has deep distribution and strong competitive moats. In those markets, smoking is still culturally normalized and regulatory barriers to entry are often low, which lets BAT maintain pricing discipline and profitability long after equivalent brands have vanished from developed markets.

The question investors must grapple with is whether BAT can transition from a shrinking business to one that manages decline gracefully and returns cash to shareholders for decades to come, or whether the secular decline in smoking will eventually overwhelm even the company’s pricing power. The most pessimistic view is that BAT is a slow-motion liquidation: the company harvests cash, returns it to shareholders, and allows the core business to shrink year by year until it no longer matters. The most optimistic view is that new-nicotine products will eventually comprise a significant share of profit and volume, extending BAT’s runway and transforming it from a tobacco company into a broader nicotine-delivery business. The truth is probably somewhere in between.

How to research BAT as an investment

Start with the annual 10-K (SEC CIK 0001303523), which breaks revenue by geography and product category and details the regulatory and litigation risks that the company faces. Quarterly earnings reports reveal the pace of volume decline and management’s confidence in pricing power to offset it. Watch the trajectory of new-nicotine revenue — it is the leading indicator of whether BAT can grow beyond the declining cigarette base.

A few metrics matter most: the dividend yield and the sustainability of dividend growth given the shrinking cash-generative base; the price-to-earnings ratio as it reflects the market’s valuation of a declining but still highly profitable franchise; and the pace of price increases versus volume declines, which reveals whether the company is truly managing decline or merely deferring the inevitable. As with any investment in a secular-decline industry, the frame is not whether BAT will be larger tomorrow than today, but whether the cash it generates and returns to shareholders will justify the price paid today.